Ebola vaccines from GlaxoSmithKline and Merck elicited antibody responses that lasted one year after vaccination, according to new research.
Young biotech Codagenix just secured $3 million in funding to advance its live-attenuated RSV vaccine candidate.
Clinical care experts and patient advocacy organizations call attention to why better patient understanding shapes the best integrated approach to orphan drug…
Sanofi will invest more than $200 million in a new plant in France to produce its newest flu vaccine, VaxigripTetra.
Affluent regions with more new moms are most likely to be spawning grounds for antivaccine tweets, a five-year study found.
Brought to you by the publisher of FierceBiotech and FiercePharma, the Fierce Innovation Awards Life Sciences Edition identify and showcase outstanding…
Here is some other vaccine news of note for this week.
A large-scale phase 3 study shows that Merck's Gardasil 9 vaccine protects against HPV-related cancers for at least six years.
As it works toward its goal of eventually licensing a low-cost pneumonia vaccine, PnuVax will have a sum of money to lean on.
Researchers in England are kicking off the world's first large human trial of a "universal" influenza shot.
The U.S. government is committing millions of dollars in support for leading Ebola vaccine programs at Merck and Johnson & Johnson.